Sunday, March 10, 2013

(CONFERENCE CONTINUES) PANCREATIC CANCER UPDATE:

*FOLFIRINOX definitely in control as first choice for first line
but this option is too toxic in the elderly so a modified version is adopted by some
.*new IMPACT STUDY,  GEMZAR-ABRAXANE is being rapidly adopted as an alternative to FOLFIRINOX for this same and very  reason (Toxicity of Folfirinox)
This combination was reportedly tried in selected clinics (including Eastern Europe) in a Phase III trial, was tried against Gemzar alone
and gave Progression free survival of 5.5 months Vs 3.7 months
                                                      Overall survival 8.5 months Vs 6.7 months     (Von Hoff DD et al.)

Abraxane given at 125 mg/m2 and Gemzar at 1000mg/m2 Q3/4 in the combination arm
----------------------------------------------------------------------------------------------
3rd choice of course was GEMZAR-ERLOTINIB follwed by GEMZAR ALONE.
===========================================================

NOTABLY NO TARGET THERAPY DISCUSSED WHICH NEEDS TO BE CORRECTED FAST!




Post a Comment